AI PRICE FORECAST
BMY Stock Forecast & AI Price Prediction
Bristol-Myers Squibb · Healthcare · Drug Manufacturers - General
BMY live signal snapshot
BMY last traded at $62.91, up 0.18% on the session, trading 8.3% below its 52-week high of $68.64 and 39.0% above its 52-week low of $45.27. The model's verdict for BMY right now: BUY (86% confidence). Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $64.36 (2.3% from here).
On the 14-day relative strength index, BMY reads 57.0, showing buyers in control without the stretch of an overbought reading. Its MACD line is above its signal line with a positive histogram (0.18) — upward momentum is accelerating. With the 50-day average at $62.10, 3.1% over the 200-day's $60.26, the longer-term trend structure remains positive.
The average 12-month target from 24 Wall Street analysts is $65.25 (range $40.00–$80.00) — 3.7% upside from where BMY trades now. The current recommendation trend leans bullish: 10 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 17 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive BMY dashboard for numbers updated throughout today's session.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company in the healthcare sector, headquartered in Princeton, NJ, United States. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It has a market value of about $128.6 billion and roughly 32,500 full-time employees. With a beta of 0.19, the stock has historically moved less than the overall market.
BMY performance vs. the market
BMY is up 16.6% so far in 2026, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 33.1%, 21.6 points better than the S&P 500. Momentum has recently turned: +11.0% in the last month against −2.7% over three months.
| Period | BMY | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +11.0% | +11.4% | −2.3% |
| 3 months | −2.7% | +12.2% | −2.3% |
| Year to date | +16.6% | +22.1% | +11.4% |
| 1 year | +33.1% | +28.3% | +11.5% |
Bristol-Myers Squibb financials at a glance
In the quarter ended Sep 30, 2026, Bristol-Myers Squibb reported revenue of $13.1 billion and net income of $2.2 billion (a 16.5% net margin). Revenue was up 6.9% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 13.9 on trailing earnings of $4.51 per share. Trailing free cash flow was $6.4 billion, and total debt equals 192% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $13.1B | $2.2B |
| Jun 30, 2026 | $13.0B | $3.3B |
| Mar 31, 2026 | $11.5B | $2.7B |
| Dec 31, 2025 | $12.5B | $1.1B |
BMY vs. its peers
Against 5 of its largest healthcare peers, BMY's +16.6% year-to-date return beats 0 of them. The strongest of the group this year is Amgen (AMGN, +43.0%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Bristol-Myers Squibb (BMY) | $62.91 | +16.6% | 13.9 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
| Amgen (AMGN) | $468.11 | +43.0% | 27.1 | BUY |
BMY stock: common questions
What is the BMY stock price target?
24 Wall Street analysts put the average 12-month target at $65.25, in a range of $40.00–$80.00, versus a recent price of $62.91. Stock Pulse 247's model projects about $64.36 over the next month.
Is BMY a buy right now?
Our AI model currently rates BMY a BUY at 86% confidence. Among analysts, 10 rate it Buy or Strong Buy, 17 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has BMY stock performed this year?
BMY is up 16.6% so far in 2026, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 33.1%, 21.6 points better than the S&P 500. Momentum has recently turned: +11.0% in the last month against −2.7% over three months.
What is BMY's 52-week high and low?
BMY has traded between $45.27 and $68.64 over the past 52 weeks; at $62.91 it is 8.3% below its 52-week high of $68.64 and 39.0% above its 52-week low of $45.27.
What sector is BMY in, and who are its peers?
BMY is in the healthcare sector (drug manufacturers - general). Its largest peers on Stock Pulse 247 include Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co. (MRK).
How accurate is the BMY forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines BMY's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.